Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Ascendiant Capital维持对novabay制药的买入评级，将价格目标调整为0.85美元（1-35股票逆向拆分）
Ascendiant Capital analyst Edward Woo maintains NovaBay Pharmaceuticals (AMEX:NBY) with a Buy, adjusts target to $0.85 from $8 (1-35 Reverse Stock Split).
Ascendiant Capital分析师Edward Woo维持买入评级novabay pharmaceuticals(AMEX:NBY)，调高目标价至$0.85，由$8调整（1-35股票逆向拆股）。
资讯热榜
更新时间